Kiniksa Pharmaceuticals International, plc last reported quarterly results on Oct 27, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $286.0 million (+58.1% year over year) and diluted EPS of $0.56. It usually reports 12–28 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 11, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Monday. Based on last year's release for the same quarter on Jan 12, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 12–28 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 27, 2026
27 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
286
+58.1%
|
47
+156.8%
|
0.56
+143.5%
|
|
Jul 28, 2026
28 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
244
+55.4%
|
25
+42.6%
|
0.30
+30.4%
|
|
Apr 28, 2026
28 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
214
+55.5%
|
23
+164.6%
|
0.27
+145.5%
|
|
Jan 12, 2026
12 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
202
+65.0%
|
14
+259.8%
|
0.17
+241.2%
|
|
Oct 28, 2025
28 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
181
+61.2%
|
18
+245.2%
|
0.23
+227.8%
|
|
Jul 29, 2025
29 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
157
+44.3%
|
18
+556.3%
|
0.23
+483.3%
|
|
Apr 29, 2025
29 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
138
+72.5%
|
9
+148.2%
|
0.11
+144.0%
|
|
Jan 13, 2025
13 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
123
+46.9%
|
-9
-135.2%
|
-0.12
-137.9%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- KNSA (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- London
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1730430
- Former names
- Kiniksa Pharmaceuticals, Ltd. (until Jun 28, 2024)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.